Ventilatory Support in Patients with COVID-19

Paolo Maria Leone, Matteo Siciliano, Jacopo Simonetti, Angelena Lopez, Tanzira Zaman, Francesco Varone, Luca Richeldi

Research output: Chapter in Book/Report/Conference proceedingChapter


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the novel coronavirus disease 2019 (COVID-19) pandemic, which spread throughout the world. Acute hypoxemic respiratory failure is the most dangerous complication of COVID-19 pneumonia. To date, no specific therapeutic drugs or vaccines have been proven efficacious. Ventilatory support is still a significant challenge for physicians facing COVID-19. The mechanisms underlying hypoxemia in those patients are not fully understood, but a new physiopathology model has been proposed. Oxygen therapy should be delivered to patients with mild to moderate hypoxemia. More severe patients could benefit from other treatments (high-flow nasal cannula, noninvasive ventilation or intubation, and invasive ventilation). Given the rapid evolution of COVID-19, there has been a paucity of the high-quality data that typically inform clinical practice guidelines from professional societies, and a worldwide consensus is still lacking. This chapter aims to illustrate the potentials of ventilatory support as therapeutic options for adult and pediatric patients affected by COVID-19 pneumonia.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
Number of pages15
Publication statusPublished - 2021

Publication series

NameAdvances in Experimental Medicine and Biology
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019


  • Acute respiratory failure
  • ARDS
  • COVID-19
  • Guidelines
  • HFNC
  • Mechanical ventilation
  • Oxygen therapy
  • Pediatric

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Ventilatory Support in Patients with COVID-19'. Together they form a unique fingerprint.

Cite this